Drugs / SB-728mR-HSPC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02500849 | Mar 2016 → Jul 2027 expected | HIV infectious disease | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-728mR-HSPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02500849 ↗ |
| Action | Inhibit | “a strategy to disrupt CCR5 genomic sequences in HSPC using zinc finger nucleases was developed” PMID 27900346 ↗ Nov 2016 |
| Modality | Cell therapy | “before being infused with the genetically modified cells” NCT02500849 ↗ |
| Target | CCR5 | “a strategy to disrupt CCR5 genomic sequences in HSPC using zinc finger nucleases was developed” PMID 27900346 ↗ Nov 2016 |